Abbreviations
amyotrophic lateral sclerosis
amyloid‐related imaging abnormalities
arteriovenous malformations
cerebral amyloid angiopathy
chemical exchange saturation transfer
cerebrospinal fluid
diffusion‐weighted imaging
focal cortical dysplasias
magnetic resonance imaging
multiple sclerosis
multiple system atrophy
Parkinson's disease
paramagnetic rim lesions
progressive supranuclear palsy
quantitative susceptibility mapping
substantia nigra pars compacta
susceptibility‐weighted imaging
Tesla
Introduction to clinical 7 Tesla MRI: a new frontier in neuroimaging
The field of neuroimaging has witnessed remarkable advancements over the past few decades. Magnetic resonance imaging (MRI) has become the gold standard for visualizing the complex structures and functions of the human central nervous system without using ionizing radiation. MRI with conventional field strengths of 1.5 and 3 Tesla (T) has thereby become a cornerstone for diagnosing many neurological disorders.
After being used as a research tool for many years, 7 T has recently also been clinically approved. This marks a significant milestone, offering potentially higher resolution (exemplified in Fig. 1 ) and greater pathological insight than ever before [ 1 ]. Although the advent of clinical 7 T MRI represented a diagnostic leap forward, it has faced technical, practical, and medical challenges. These have, to a large extent, been addressed by recent hardware and software advancements in a second generation of clinical 7 T MRI, addressing prior limitations and making routine clinical use feasible.
This review explores recent technical innovations in clinical 7 T MRI and the diagnostic value it brings to patient care. Based on experience from over 1200 clinical scans conducted with a second‐generation system in the first year of operation, we provide practical insights and highlight its potential to redefine diagnostics and treatment in neurological disorders.
Technical advancements and their clinical benefit
Clinical approval and hardware improvements
Clinical approval of 7 T MRI, achieved in 2017, marked a milestone in ultra‐high‐field neuroimaging [ 1 ]. The introduction of second‐generation systems in 2023 has addressed key challenges of earlier models, further advancing clinical adoption.
Producing 7 T magnets—over 100,000 times stronger than Earth's magnetic field—requires helium‐cooled superconducting environments and robust magnetic shielding. Modern innovations have reduced the size and weight of 7 T scanners, enabling hospital integration despite weighing over 20,000 kg, almost double that of a 3 T scanner. Notably, though, the physical dimensions are now on par with 1.5 T scanners from the 1990s, making it possible to repurpose older bays for MRI scanners in hospitals for 7 T MRI. Active shielding has also minimized fringe fields, reducing the MRI safety zone footprint.
A key challenge in clinical 7 T MRI is achieving homogenous image quality across the brain and spinal cord, especially near air‐filled structures, such as paranasal sinuses, temporal bones, and the lungs. Innovations such as parallel transmission—using multiple transmit channels—make it possible to tailor radio waves suitable for each patient [ 2 ]. This translates into more homogenous image intensities, as exemplified in Fig. 1 , and is particularly valuable in, for example, presurgical evaluation of temporal lobe epilepsy and detecting infratentorial lesions in multiple sclerosis (MS).
Software improvements
Recent software advancements have significantly streamlined the operation of 7 T MRI systems, aligning them with conventional clinical scanners. Automated shimming, slice positioning, and standardized graphical user interfaces now reduce the need for advanced application training. These improvements simplify integration into clinical workflows.
Deep learning–based tools have transformed imaging by reducing scan times while maintaining, or even enhancing, image quality [ 3 ]. Faster scans improve patient comfort, minimize motion artifacts, and boost throughput, which is critical for high‐cost systems such as 7 T MRI. Additionally, deep learning enhances resolution, contrast, and image consistency by addressing intensity variations. These innovations enable more accurate diagnoses, particularly for subtle pathologies, and support disease monitoring and treatment evaluation.
Practical considerations
Safety and operational considerations
The increased magnetic field strength of 7 T MRI poses no known long‐term health risks but introduces unique challenges. Scanning is typically performed in “First Level Controlled Operating Mode,” requiring medical supervision due to elevated radiofrequency and gradient fields. Specific absorption rate limits and tissue heating demand careful monitoring, often necessitating longer acquisition times and individualized adjustments for safety.
Practical limitations include the lack of testing for many implants at 7‐T, restricting its use in patients with implanted devices—relatively common among elderly patients with neurological diseases. Additionally, current head coils have a weight limit of 30 kg, precluding imaging in small children, and the absence of 7 T MRI‐compatible ventilators further limits use in pediatric or sedated patients. Clinical approval is also limited to brain imaging, as spinal cord coils remain under development. This necessitates the use of multiple scanners for combined brain and spinal cord imaging, such as in neuroinflammatory disorders.
These factors collectively underscore the importance of balancing the benefits of enhanced imaging capabilities of 7 T MRI with stringent safety measures to minimize potential risks.
Patient experience
Seven Tesla scanners retain the conventional bore size of 60 cm, which can feel restrictive compared to newer wide‐bore designs at 0.55 (80 cm), 1.5, and 3 T (70 cm). Patients may—similarly to scanning at conventional field strengths—experience sensory effects such as tingling or light vertigo during scans, which are generally mild and transient. Educating patients about these sensations and noise levels helps improve comfort and acceptance, crucial for clinical integration.
Workflow and training
Effective adoption of 7 T MRI into clinical workflows demands collaboration among MRI physicists, radiologists, and technologists. Pathology‐specific protocols must balance resolution with scan time, catering to diverse clinical needs. Training radiologists in interpreting 7 T images is essential, as these scans reveal details not observable at lower field strengths. Continuous vendor support and user feedback are key to refining protocols and leveraging the system's full potential.
Financial and infrastructure considerations
The high cost of 7 T MRI systems, coupled with increased operational expenses, presents a significant barrier. Any infrastructure modifications needed at installation as well as service contracts add to the financial burden. Institutions must carefully weigh these costs against clinical benefits, ensuring sufficient patient throughput and reimbursement models to justify investment. In practice, reimbursement strategies differ among regions, and 7 T MRI often lacks specific/higher reimbursement, making it challenging to build a financial case for the scanner.
Clinical applications of 7 T MRI in neurological disorders
Growing evidence underscores the clinical utility and cost‐effectiveness of 7 T MRI in neurological disorders. This section highlights its key clinical applications, emphasizing enhanced diagnostic accuracy and deeper pathophysiological insights.
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative disorder characterized by dysfunction of both upper and lower motor neurons. Upper motor neuron pathology involves the loss of pyramidal neurons in the primary motor cortex along with axonal loss and gliosis in the corticospinal tracts, where reactive, iron‐laden microglia and macrophages are abundant [ 4 ]. Assessing upper motor neuron burden currently relies on clinical evaluation, which is often confounded by overlapping lower motor neuron degeneration. Although electrophysiological tests provide insights into lower motor neuron dysfunction, a robust in vivo imaging biomarker for upper motor neuron impairment remains an unmet need [ 5 ]. The integration of 7 T MRI into clinical practice is advancing these possibilities, significantly enhancing the qualitative and quantitative detection of motor neuron pathology [ 6 ].
The motor band sign has emerged as a promising imaging biomarker for ALS. This rim‐like cortical hypointensity reflects iron accumulation within microglial cells in the deeper layers of the primary motor cortex, typically visualized along the posterior border of the primary motor cortex, as exemplified in Fig. 2 . It is most effectively detected using T2* ‐weighted imaging, susceptibility‐weighted imaging (SWI), or quantitative susceptibility mapping (QSM), which exploit the paramagnetic properties of iron to highlight these accumulations [ 7 ].
Although the motor band sign is occasionally observable with 1.5‐ and 3 T MRI [ 7 , 8 ], the superior spatial resolution and increased sensitivity to field inhomogeneities of 7 T MRI allow for a more detailed characterization of iron deposition, as demonstrated both in vivo [ 5 ] and ex vivo [ 4 ]. Studies show that the motor band sign is present in a majority of patients with ALS on 7 T MRI, correlating with clinical presentation and the severity of the upper motor neuron burden [ 5 , 9 ].
Another imaging biomarker in ALS is the T2 hyperintensities along the corticospinal tracts, which have been suggestive of upper motor neuron degeneration in ALS [ 10 ], with a clear depiction on 7 T in Fig. 2 .
Epilepsy
Approximately onethird of persons with epilepsy have drug‐resistant epilepsy, and among these, 30%–40% lack detectable lesions on 1.5‐ and 3 T MRI. Several studies have investigated the utility and challenges of 7 T MRI in the diagnostic work‐up of epilepsy [ 11 ], consistently demonstrating its superiority in detecting intracranial lesions or abnormalities compared to lower field strengths [ 12 , 13 , 14 ]. A pooled analysis reported a 31% diagnostic gain with 7 T MRI over conventional field strengths [ 11 ]. The increased signal‐to‐noise ratio at 7 T enables improved visualization of cortical components, including a more precise delineation of the gray–white matter interface. This enhancement improves the sensitivity for identifying epileptic lesions, such as focal cortical dysplasias (FCD), hippocampal sclerosis, and amygdala abnormalities [ 11 ], facilitating more accurate surgical planning and more favorable outcomes [ 15 ].
Focal cortical dysplasia
FCD is the most frequently resected epileptic lesion in children and the third most common in adults [ 16 ]. It involves localized cortical malformations with diverse histopathological features, classified into three subgroups (Types I–III). On MRI, FCD is characterized by increased cortical thickness, blurred gray–white matter junctions, transmantle signs, or abnormal gyral/sulcal patterns [ 17 , 18 ]. Fig. 3 exemplifies FCD in a pediatric patient.
These subtle features are often overlooked on lower field‐strength MRI, particularly in lesions located deep within a sulcus. FCD is the most common etiology in patients undergoing surgery for refractory focal “non‐lesional” epilepsy, with visibility varying by subtype—Types I and IIa being the least detectable on 1.5‐ and 3 T MRI [ 17 , 19 ]. However, 7 T MRI has been shown to significantly enhance diagnostic yield in these cases [ 13 , 20 ].
At 7 T, thin‐slice 2D T2‐weighted imaging and 3D T1‐weighted imaging remain key techniques, with MP2RAGE being particularly useful at 7 T due to its high‐resolution imaging and ability to mitigate transmit field inhomogeneities [ 21 , 22 ]. Additionally, 7 T T2*‐weighted imaging can reveal the black line sign—a distinctive intracortical hypointense band found in FCD Type IIb. Complete resection of this black line correlates with improved postsurgical seizure outcomes [ 19 , 23 ].
Hippocampal sclerosis
Hippocampal sclerosis, the most common histopathological hallmark of temporal lobe epilepsy, involves atrophy, signal changes, and disruption of hippocampal internal architecture [ 24 , 25 ]. It can be classified into four subgroups with varying prognoses for postoperative seizure control and memory function [ 26 ]. Conventional MRI primarily distinguishes hippocampal sclerosis from non‐sclerosis but provides limited detail on substructures. In contrast, 7 T MRI offers enhanced visualization of hippocampal internal architecture and enables detection of subtle pathological changes [ 27 , 28 , 29 ]. Fig. 3 exemplifies hippocampal sclerosis in an adult patient.
Polymicrogyria
Polymicrogyria—a malformation of cortical development commonly associated with epilepsy and developmental delays—benefits significantly from 7 T MRI. The improved spatial resolution at 7 T enables more detailed morphological assessments, such as visualization of dilated veins in affected areas, which are often undetectable at lower field strengths [ 30 ].
Dementia
Dementia is caused by neurodegenerative disorders characterized by declining cognitive functions, including diseases such as Alzheimer's disease (AD), vascular dementia, Lewy body dementia, frontotemporal dementia, and less common diseases such as Creutzfeldt–Jakob disease. The most common form of dementia is AD, representing 60%–80% of all dementia types.
In clinical practice today, MRI plays a role in excluding other causes of cognitive decline as well as evaluating signs of small vessel disease, such as white matter changes, infarctions, microbleeds, and perivascular spaces, and determining the degree of cortical and hippocampal atrophy, which is typically assessed through visual inspection on 1.5‐ or 3 T MRI. Structural volumetric analysis has been used in research and clinical trials and is now increasingly used clinically. Although image inhomogeneities at higher field strengths remain a challenge, 7 T MRI and high‐resolution imaging enable more precise measurements of small anatomical regions, such as the hippocampus and subcortical structures [ 31 ].
Hippocampal subfield segmentations
Morphometric changes in the medial temporal lobe can serve as imaging markers for early AD due to the deposition of abnormal proteins in these regions [ 32 ]. Atrophy in the hippocampus and entorhinal cortex are markers in early AD and its prodromal stages, such as mild cognitive impairment. The hippocampus consists of several subfields—including the cornu ammonis, which is divided into four sectors, the dentate gyrus, and the subiculum. The superior spatial resolution with 7 T MRI allows for better delineation of these subfields, thus enabling the detection of subtle changes in the hippocampus [ 28 , 33 , 34 ]. Studies have shown that cornu ammonis 1 is one of the first regions for atrophy in AD [ 35 ]. Early detection of changes associated with AD is crucial for this patient group to initiate treatment before memory and functional decline in order to slow the progression of the disease.
Microbleeds
Microbleeds are defined as small round or ovoid foci of blood products, which can be detected on SWI due to the paramagnetic properties of hemosiderin. Increased magnetic field strength improves the detection of microbleeds due to enhanced susceptibility effects [ 36 ]. Seven Tesla MRI provides significantly superior detection of microbleeds compared to 3 T, increasing the detected prevalence in AD and mild cognitive impairment from 33% to 78%. The higher sensitivity of 7 T MRI can help in treatment decisions—for example, concerning the use of antithrombotic therapies in this patient group [ 37 ].
Cerebral amyloid angiopathy and amyloid‐related imaging abnormalities
Cerebral amyloid angiopathy (CAA) is a small vessel disease common in patients with AD, sharing similar pathomechanistic pathways involving amyloid beta deposition within the cerebral vessel walls, causing weakening of the vessels, microaneurysms, and increased risk of intracranial hemorrhage. Both diseases share the APOE ε4 allele as a common risk factor. Imaging markers for CAA include lobar microbleeds and cortical superficial siderosis, with improved detection at higher magnetic field strengths [ 36 , 38 ]. Inflammatory CAA is a rare and aggressive subtype characterized by asymmetric, patchy, or confluent white matter lesions that may extend to the cortex along with multiple lobar microbleeds [ 39 ].
Monoclonal antibodies targeting amyloid beta are emerging therapies for early AD: Donanemab and lecanemab were recently approved for clinical use in the United States and have shown promising results in patients with mild cognitive impairment and early AD [ 40 ]. In November 2024, lecanemab was also approved by the European Medicines Agency [ 41 ] for treating these patients if they only have one or no copy of the APOE ε4 allele, reducing the risk of amyloid‐related imaging abnormalities (ARIA). Another risk factor for developing ARIA is CAA. ARIA is classified into ARIA‐E (edema/effusion), characterized by T2 hyperintensities that often resolve over time, and ARIA‐H (hemosiderin) with microbleeds and superficial hemosiderosis. Most ARIA cases are asymptomatic [ 42 , 43 ]. However, it is crucial to identify patients with ARIA to prevent severe complications such as intracerebral hemorrhage by temporarily or permanently discontinuing the treatment. The higher sensitivity of 7 T MRI for microbleeds and siderosis may thus be translated into a more sensitive tool for monitoring these treatment‐related side effects, and it is especially useful in patients with risk factors such as CAA or the APOE ε4 allele [ 6 , 42 ].
Creutzfeldt–Jakob disease
Creutzfeldt–Jakob disease is a rare prion disease with rapid progressive neurodegeneration. Brain MRI is often helpful in identifying these patients among memory clinic patients due to typical MRI findings, with a topography dependent on the subtype (sporadic, familial, and variant). Creutzfeldt–Jakob disease causes T2 hyperintensities in the cerebral cortex and the deep gray matter, usually the putamen and caudate nucleus, with corresponding restricted diffusion on diffusion‐weighted imaging (DWI). Often, the diffusion restriction pattern can be pathognomonic, as exemplified in Fig. 2 .
Multiple sclerosis
MS is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system. It is a leading cause of neurological disability in younger adults. MS is characterized by acute inflammatory demyelinating events causing neurological symptoms with or without recovery. The MS diagnosis is based on clinical, imaging, and laboratory evidence with dissemination in time and space, with MRI being the cornerstone of diagnostics and disease monitoring [ 44 , 45 ]. Increased magnetic field strength can provide better visualization of subtle pathologies and MS‐specific biomarkers, leading to earlier diagnoses and treatment, which is crucial for a better prognosis [ 46 ]. The 2024 revisions to the McDonald criteria—presented at ECTRIMS 2024 but not officially published at the time of publication of this article—put even more emphasis on radiological markers such as the central vein sign and paramagnetic rim lesions (PRLs) [ 47 ].
White matter lesions
The myelin loss in focal MS lesions is visualized on MRI as T2 hyperintense lesions, especially on fluid‐attenuated inversion recovery (FLAIR) sequences in which the signal from cerebrospinal fluid (CSF) is eliminated [ 48 ]. In 7 T MRI, FLAIR imaging has limitations because of increased field inhomogeneity in both the static magnetic field (B0) and the radiofrequency transmit field (B1). Therefore, other sequences—such as 3D T1‐weighted images—have a pivotal role to discriminate focal MS lesions [ 21 , 49 ].
Seven Tesla MRI allows for smaller voxels, leading to enhanced spatial resolution and enabling the detection of a higher number of lesions within the white matter compared to 1.5‐ and 3 T MRI. Notably, confluent lesions on 3 T have been shown to be multiple smaller lesions using 7 T [ 50 ]. Furthermore, normal‐appearing white matter—which shows diffuse abnormalities on quantitative MRI sequences—may represent focal lesions that are not visible at lower magnetic field strengths [ 46 ].
Cortical lesions
For many years, MS was considered a white matter disease. With the advent of 7 T MRI in research, it has repeatedly been shown that this is not a correct categorization. In fact, both the cortex and deep gray matter are affected by focal and diffuse MS pathology. Notably, 93% of patients with MS have been shown to have cortical lesions in the early disease stages [ 51 ]. Furthermore, longitudinal 7 T scanning has shown that the lesion accrual rate is higher in the cortex than the white matter [ 52 ]. Importantly, cortical lesions are an independent predictor of future cognitive and physical impairment in MS [ 53 , 54 ].
Although cortical lesion detection is challenging at conventional field strengths—even with dedicated cortical imaging sequences—their detection remains an unmet clinical need because cortical lesions have high diagnostic specificity for MS and have been included in the diagnostic criteria since 2017 [ 44 ]. Due to the prevalence of MS and the importance of early diagnosis and treatment to avoid physical and cognitive dysfunction, this is perhaps the most impactful of all clinical applications of clinical 7 T MRI. Due to the thin cortical ribbon and proximity to CSF (which may obscure small cortical lesions due to partial volume effects), the higher spatial resolution and improved contrast‐to‐noise ratio of 7 T MRI provide improved detection of cortical MS lesions—especially the subpial lesions, the most common type [ 52 , 55 , 56 ]. For this purpose, T2*‐weighted imaging is particularly useful [ 57 ], as exemplified in Fig. 4 and Supporting Information video 1 .
Paramagnetic rim lesions
PRLs are an emerging and specific marker for MS that were implemented in the diagnostic criteria in the 2024 revision [ 47 ]. They can be identified as hypo‐ or hyperintense rims surrounding the lesion on susceptibility‐weighted sequences, such as T2*, SWI, or QSM—with SWI being the most commonly used sequence in clinical practice [ 58 ]. The paramagnetic rim represents the accumulation of iron‐laden macrophages at the lesion edge—representing ongoing inflammation—whereas the core of the lesion is demyelinated. These findings correspond to chronic active lesions [ 59 ]. PRLs have been associated with worse clinical outcomes, higher lesion volumes, and more brain atrophy. PRLs are also more destructive compared to non‐PRLs, and the presence of PRLs has been proposed as a marker for progressive disease [ 60 , 61 , 62 ]. PRLs can be detected on 1.5‐ and 3 T MRI. However, 7 T MRI provides increased sensitivity for detection due to enhanced susceptibility effects [ 63 ], as exemplified in Fig. 4 .
Central vein sign
Another emerging MS biomarker—which was also integrated into the diagnostic criteria in 2024—is the central vein sign [ 47 ]. MS is characterized by perivenous pathology marked by the accumulation of inflammatory cells surrounding venules. These small veins can best be visualized in the center of MS lesions on susceptibility‐weighted sequences. Studies have demonstrated that the central vein is present in >85% of MS lesions and a minority of cases in other neuroinflammatory diseases. Therefore, the central vein sign constitutes a diagnostic tool to differentiate MS from other related conditions [ 48 ]. In 7 T MRI, veins are better delineated due to their paramagnetic properties from deoxygenated blood. Studies have shown that 7 T MRI outperforms 3 T MRI in the detection of a central vein with a 100% sensitivity and specificity for MS [ 64 , 65 ]. As shown in Fig. 4 , central veins are clearly depicted.
Leptomeningeal enhancement
Typically, MS lesions are located in proximity to the CSF, around the ventricles and the cerebral cortex. It has been proposed that meningeal inflammation and CSF‐mediated factors may play a key role in the pathogenesis of MS [ 66 ]. Visualizing meningeal inflammation has been a challenge on lower magnetic field strengths. Using gadolinium‐enhanced FLAIR imaging at 7 T, leptomeningeal enhancement was observed in 90% of patients with MS in one study. These findings are consistent with observations from postmortem studies. For this reason, 7 T MRI may be useful in diagnosing meningeal pathology [ 67 ]. However, leptomeningeal enhancement is not specific for MS and can be seen in other neuroinflammatory diseases as well as non‐inflammatory neurological diseases [ 68 , 69 ].
Parkinsonisms
Parkinsonism is an umbrella term for progressive neurodegenerative movement disorders characterized by symptoms, such as rigidity, bradykinesia, and tremors, mainly affecting the elderly population. This category includes various diseases, with Parkinson's disease (PD) being the most common, representing about 80% of all cases. Other forms of parkinsonism include multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). It can be challenging to clinically differentiate PD, PSP, and MSA due to overlapping symptoms [ 70 ].
The pathology in PD is characterized by loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The SNpc is subdivided into the matrix and five nigrosomes. Nigrosome‐1 is the largest, and it contains the highest concentration of neuromelanin‐rich dopaminergic neurons [ 71 , 72 , 73 ].
The higher spatial resolution and contrast of 7 T enable clearer depiction of small anatomical structures such as the subthalamic nucleus, s, red nucleus, and the basal ganglia. This is particularly beneficial in MRI‐guided treatments such as deep brain stimulation, which targets deep nuclei to manage movement disorders such as PD [ 74 , 75 ].
Seven Tesla MRI enables more detailed imaging of subregions within the suSN and better visualization of nigrosomes in the SNpc. This improves the detection of abnormal brain architecture in PD [ 71 ]. A study on neuromelanin 7T imaging of the SN showed that patients with PD exhibited significantly lower SNpc volumes compared to non‐PD, and PD volume was highly specific and sensitive for differentiating PD from non‐PD and essential tremor [ 76 ].
The so‐called swallow tail sign represents the normal appearance of the SN on SWI [ 77 ], characterized by a dorsolateral hyperintensity within two hypointense layers, resembling a swallow's tail. The hyperintensity on MRI corresponds to nigrosome‐1 [ 32 , 78 ]. The loss of the swallow tail sign reflects the degeneration of dopaminergic cells within nigrosome‐1 accompanied by iron accumulation and loss of neuromelanin, and it has been proposed as a diagnostic marker for PD [ 79 ]. The absent hyperintensity within the SNpc on 7 T T 2*‐weighted imaging has been shown to be highly sensitive and specific for PD [ 78 , 80 ]. This marker can help distinguish PD from other movement disorders. However, patients with PSP and MSA may also exhibit an absent nigrosome‐1 [ 71 ].
QSM in parkinsonism
QSM is a post‐processing method from the MRI phase images that quantifies iron, calcium, and blood compounds by measuring their effects on local magnetic susceptibility shifts. Using deconvolution, QSM converts magnetic field variations into susceptibility maps. This provides a more accurate measurement of tissue susceptibility compared to other methods [ 81 ].
In PD, iron accumulation is linked to the loss of dopamine neurons in the SNp due to oxidative stress resulting in neuronal damage. Studies on 3 T MRI have shown that patients with PD have higher susceptibility values in the SN compared to healthy controls [ 82 , 83 ]. QSM is a valuable tool for potential early diagnosis and disease monitoring. Additionally, QSM may be useful for assessing treatment efficacy by tracking changes in iron levels within the SN [ 84 ].
QSM at 7 T offers significant advantages due to the more pronounced phase shifts at higher magnetic field strengths. This makes it easier to detect variations in magnetic susceptibility, leading to better differentiation between tissues as well as the ability to identify subtle changes in tissue composition. Furthermore, the higher spatial resolution of 7 T MRI provides more accurate susceptibility maps by allowing for more precise mapping of susceptibility variations [ 85 , 86 ].
The red nucleus, located near the SN, is another region with a high concentration of iron. It is a component of the cerebellar circuitry, often affected in these conditions. Studies using QSM at 3 T found that patients with PSP had significantly higher susceptibility within the red nucleus compared to those with PD, MSA, and healthy controls [ 87 ]. Another study could further confirm that the red nucleus shows elevated iron content in PSP, making it a promising marker for differentiating PSP from other parkinsonisms [ 73 ].
Tumors
The increased magnetic field strength of 7 T MRI enables more detailed visualization of fine structures, such as tumor margins, microvasculature, small lesions, microbleeds, and subtle anatomical changes that might be missed at conventional field strengths. This is particularly useful for identifying early signs of tumor growth or recurrence and for detailed mapping of tumor‐associated vasculature [ 88 , 89 ].
Compared to 3 T, 7 T can provide greater contrast between healthy white matter and glioblastoma tissue, with enhanced visualization of tumor infiltration into adjacent white matter tracts [ 85 ] and improved demarcation of tumor boundaries. The improved delineation of tumor borders can help spare more healthy brain tissue. Incorporating 7 T MRI into neurosurgical navigation and radiotherapy treatment planning is technically feasible and safe [ 90 ].
SWI and DWI techniques are instrumental in analyzing brain structures such as microbleeds and tumor vasculature, aiding in preoperative tumor grading, tumor microstructure characterization, and visualizing radiation therapy injuries [ 89 ].
Glioma diagnosis traditionally requires histopathological analysis, with MRI providing grade estimation based on contrast enhancement, which has limitations. Imaging techniques such as SWI are particularly useful in visualizing neovascularization in malignant gliomas and venous structures and have the potential to improve accuracy. Longitudinal studies using 7 T SWI have tracked tumor vasculature changes during anti‐angiogenic therapy, highlighting changes in brain edema, microhemorrhages, and intratumoral irregularities. SWI is also effective in assessing radiation‐induced injuries [ 91 , 92 , 93 ]. Additionally, 7 T SWI can provide quantification of intratumoral vascular complexity via fractal dimension analysis—correlating with tumor grades—and SWI‐derived local image variance has been linked to tumor grade and IDH status [ 94 ].
The ability of DWI to visualize tissue microstructures has been validated [ 95 ] for glioma evaluation, with 7 T providing a superior tissue complexity visualization compared to 3 T. This reveals unique tissue information absent in anatomical images. Consistently acquiring high‐quality diffusion data at 7 T is challenging but will support the implementation of comprehensive brain MRI examinations at ultra‐high fields.
Vascular disorders
Vascular MRI imaging techniques
MRI provides an alternative to computed tomography angiography and digital subtraction angiography without ionized radiation [ 96 , 97 ]. Notably, time‐of‐flight MRI angiography is a contrast agent‐free technique ideal for patients with contraindications for contrast administration such as renal insufficiency or pregnancy [ 96 ]. Compared to conventional field strengths, 7 T MRI enables visualization of intracranial vessels in more detail—especially small branches—through higher spatial resolution and longer T1 relaxation of background tissues, which increases the contrast by improving background suppression [ 98 ]. Examples of 7 T arterial time‐of‐flight angiography and SWI for vascular imaging are provided in Fig. 2 .
Atherosclerosis
Intracranial atherosclerosis is defined as atherosclerotic plaques in the large intracranial arteries resulting in increased vessel wall thickness, and it is a common cause of recurrent strokes [ 99 ]. With vessel wall MRI, these plaques can be visualized as focal wall thickening within the arterial lumen, showing contrast enhancement primarily at the fibrous cap region. Vessel wall imaging can be improved at 7 T relative to 1.5 and 3 T due to increased signal‐to‐noise ratio and smaller voxels, which are beneficial for detecting subtle pathologies. Moreover, higher magnetic field strength contributes to enhanced CSF suppression, thereby improving image quality in vessel wall imaging by minimizing artifacts arising from the CSF [ 100 , 101 , 102 ].
Aneurysm
Intracranial aneurysms are estimated to occur in 0.5%–3% of the population and contribute to 80%–85% of cases of non‐traumatic subarachnoid hemorrhages. Various factors—including aneurysm size, location, and patient age—play roles in determining the risk of rupture [ 103 ]. The identification of contrast enhancement within the aneurysm wall has been proposed as an indicator of increased risk of rupture, which can be detected through vessel wall MRI. In addition, contrast enhancement within the wall is a potential marker for assessing the probability of a certain aneurysm having ruptured or the risk of developing vasospasm after rupture. The enhanced spatial resolution provided by 7 T leads to a more accurate characterization of the aneurysm wall in terms of thickness, layers, contrast enhancement, and the ability to detect smaller aneurysms compared to lower magnetic field strengths [ 104 ].
Vasculitis
Cerebral vasculitis is characterized by inflammation of vessel walls within the central nervous system. Early detection is key to halting the disease's course and preventing irreversible brain damage. Angiographic techniques are used to visualize vasculitis‐related pathology—typically as localized or multifocal segments of stenosis of the intracranial arteries, with a predilection for the middle cerebral artery. In addition, bilateral infarctions across multiple vascular territories may be present [ 105 ]. The improved resolution with 7 T imaging offers a significant advantage in the detection of vasculitis, as it heightens the visibility of smaller intracranial vessels [ 98 ]. Furthermore, high‐resolution vessel wall imaging may aid in differentiating vasculitis from conditions such as atherosclerosis. A study on 3 T MRI demonstrated different enhancement patterns, characterized by eccentric enhancement in atherosclerotic plaques and concentric enhancement in inflammation, thereby improving diagnostic precision [ 106 ].
Arteriovenous malformations
Arteriovenous malformations (AVMs) are high‐flow vascular abnormalities where a nidus connects arterial feeders to draining veins, leading to arteriovenous shunts, vessel hypertrophy, and potential complications such as hemorrhage from ruptured flow‐related aneurysms, venous thrombosis, and infarction due to blood bypassing the brain parenchyma [ 107 ]. Seven Tesla MRI is comparable to digital subtraction angiography for evaluating AVMs, as it enables the detection of small flow‐related aneurysms (less than 2–3 mm) and provides a detailed characterization of vascular territories for feeding arteries and draining veins [ 108 ]. Another technique called 4D flow MRI enables quantitative examination of blood flow within vessels, providing insights into hemodynamics within AVMs and other cerebrovascular diseases with disturbed blood flow, such as Moyamoya disease. Improved resolution is crucial for capturing hemodynamic alterations within small vessels and aneurysms, which previously was a limitation with 4D flow MRI at lower magnetic field strengths [ 109 ].
Cavernous malformations
Cavernous malformation, also called cavernoma, constitutes 8%–15% of all vascular malformations and is characterized by clusters of dilated, thin‐walled capillaries containing hemosiderin deposits within and surrounding the lesions. Typically, these lesions remain asymptomatic; however, in rare instances, they can cause hemorrhage, particularly when combined with developmental venous anomalies [ 110 ]. Due to the paramagnetic properties of hemosiderin, these lesions are visualized best on SWI. With 7 T MRI, the sensitivity to detect cavernomas is significantly improved through increased susceptibility effects, and even microscopic lesions can be visualized [ 111 ].
Functional and metabolic imaging
fMRI
Task‐based functional MRI (fMRI) is routinely used for presurgical planning to identify eloquent brain regions, such as those governing speech and motor functions [ 112 ]. Clinical 7 T MRI enhances this process by offering superior spatial resolution and more precise delineation of functional areas. By improving the accuracy of these maps, 7 T fMRI helps minimize the risk of postoperative deficits in patients undergoing surgery for brain tumors, epilepsy, or vascular malformations, providing a significant clinical advantage over lower field systems.
Another advantage with 7 T MRI is that it can provide layered fMRI, disentangling the activation and inhibition within individual cortical layers. This precision is crucial for understanding the directional flow of information within cortical circuits, as it permits differentiation between feedforward and feedback processes across layers [ 113 ]. Although this presently does not hold immediate clinical diagnostic value, it may help us better understand network diseases such as epilepsy and give insight into disrupted communication pathways in disorders, such as depression, schizophrenia, and anxiety. These advances may inform the development of targeted therapeutic strategies in the future, bridging the gap between neuroimaging research and clinical psychiatry.
Spectroscopy
Proton magnetic resonance spectroscopy is a non‐invasive imaging technique that quantifies brain metabolites in vivo, including N ‐acetylaspartate (neuronal integrity), creatine (energy metabolism), choline (cell membrane turnover), myo ‐inositol (glial activation), and neurotransmitters such as glutamate (excitatory) and GABA (inhibitory) [ 114 ]. In clinical practice, proton magnetic resonance spectroscopy is routinely applied to evaluate metabolic disorders in children and can detect lactate peaks for distinguishing brain abscesses from other pathologies.
The increased spectral resolution and signal‐to‐noise ratio at 7 T enable precise quantification of low‐concentration metabolites and resolution of overlapping spectral peaks [ 115 ]. This is particularly valuable for researching neurological and psychiatric disorders with improved measurements of glutamate and GABA, aiding in the understanding of epilepsy, depression, and schizophrenia. The enhanced resolution also supports regional metabolic assessments in conditions, such as brain tumors, MS, ALS, and AD [ 115 , 116 , 117 ].
CEST
Metabolic imaging at 7 T MRI, particularly using chemical exchange saturation transfer (CEST) techniques, has shown advanced capabilities for tumor characterization and treatment monitoring. Variants, such as amide‐proton‐transfer CEST, glutamate‐CEST, and glucose‐CEST, leverage the improved frequency dispersion at 7 T to enhance signal specificity, enabling applications such as tumor grading, prediction of treatment efficacy, and identification of genetic mutations such as IDH status and MGMT promoter methylation [ 118 , 119 , 120 , 121 ]. Studies have demonstrated that glucose‐based CEST methods provide superior tumor border identification and contrast enhancement without the risks associated with gadolinium agents, showing significant promise for non‐invasive, high‐resolution metabolic imaging at 7 T [ 122 , 123 , 124 , 125 ].
X‐nuclei imaging
Typically, clinical MRI is based on imaging the spin of protons, which are abundant in the human body with its high water content. However, MRI also has the potential to visualize other elements with spin that are crucial for numerous physiological processes, providing opportunities for non‐invasive metabolic imaging without ionizing radiation. This imaging technique is known as X‐nuclei, non‐proton, or multinuclear MRI [ 126 ]. Examples of X‐nuclei used in biomedical applications are 13 C, 17 O, 19 F, 23 Na, and 31 P [ 127 ]. In comparison to 1 H, X‐nuclei have a much lower abundance in vivo, which limits the signal‐to‐noise ratio, making it an attractive 7 T application [ 74 ]. Because different X‐nuclei are involved in distinct physiological activities, X‐nuclei imaging techniques can be used to study a broad spectrum of diseases [ 127 , 128 ]. Although X‐nuclei imaging shows promise for metabolic imaging, especially at 7 T MRI, it remains thus far mainly a tool for research and better pathophysiological understanding of diseases.
Future directions
Clearly, clinical 7 T MRI holds significant potential for advancing diagnostic precision and patient care across neurological conditions. To further improve the clinical value, future efforts should build on existing knowledge to define clinical standards in terms of protocols and standard operating procedures for safety management. Establishing a common database on known safe, conditional, and tested implants would be especially valuable. Sharing experiences through international collaborations among early‐adoption sites is also encouraged to establish harmonization for clinical 7 T MRI. This is a necessary step to build a foundation for multicenter trials and the ability to pool and validate data across sites.
Medical professionals and vendors will need to work together with legislators and insurers to help define the clinical and monetary value of the medical advances that 7 T MRI provides in order to correctly reimburse such scans and make them more available in clinical practice.
Additional hardware and software solutions can bring improvements and expand clinical applications. Field monitoring probes can reduce artifacts and improve image quality [ 129 ]. Improved head–neck coils and spinal coils can make it possible to image the whole neuroaxis in one session [ 130 ]. Future efforts should continue leveraging high‐gradient performance to further use quantitative imaging techniques to probe microstructural properties and gain improved biological tissue specificity [ 130 ]—for example, through myelin imaging, QSM, and advanced diffusion imaging. Notably, a head‐only 7 T system equipped with ultra‐high gradients of 200 mT/m and a slew rate of 900 T/m/s has already been developed [ 130 ].
Moreover, the technical capabilities of the second‐generation clinical 7 T scanner provide unique opportunities to bridge the mesoscale gap between in vivo imaging and gold‐standard histopathology. Notably, ex vivo MRI at ultra‐high resolution (150 µm, exemplified in Fig. S1 ) presents opportunities to improve our understanding of underlying pathophysiology, guide targeted advanced histopathological analysis, and identify new treatment targets.
To continue pushing the frontiers of neuroimaging, additional effort should leverage the capabilities of 7 T and higher field strengths (10.5, 11.7, and even 14 T) [ 113 ]. From a sustainability standpoint, developing cryogen‐free magnet designs will ensure broader accessibility and environmental responsibility [ 131 ].
Conclusions
Clinical 7 T MRI represents a transformative advancement in neuroimaging, offering unparalleled diagnostic precision. Its application in neurological disorders, such as ALS, MS, dementia, parkinsonism, tumors, and vascular diseases, allows for earlier diagnoses, enhanced lesion characterization, and improved treatment planning. Emerging biomarkers used clinically today—such as the motor band sign, central vein sign, and PRLs—highlight its potential to redefine disease understanding and management. Innovations in hardware, software, and safety protocols are addressing previous limitations and expanding accessibility. Future efforts should focus on standardizing protocols, enabling multicenter collaborations, and integrating 7 T MRI into routine practice through demonstrated cost‐effectiveness. By bridging research and clinical care, 7 T MRI has the potential to reshape the diagnostic and therapeutic landscape in neurology.
Author contributions
Tobias Granberg initiated the study. Russell Ouellette, Elisabeth de Vries, and Tobias Granberg created figures. Tobias Granberg, Elisabeth de Vries, Caroline Hagbohm, and Russell Ouellette drafted the manuscript. All authors revised the manuscript critically and approved the final version of the manuscript.
Conflict of interest statement
The authors declare no conflicts of interest.
Funding information
No specific funding was obtained to perform this study.
Supporting information
Fig. S1 . Ex vivo 7 Tesla MRI (isotropic 150 µm resolution) showing extensive subpial (Types III and IV) cortical multiple sclerosis lesions.
Supplemental video . In vivo clinical 7 Tesla MRI showing multiple sclerosis white matter and gray matter lesions using axial 2D T 2*‐weighted gradient‐recalled echo with a resolution of 0.3 × 0.3 × 0.9 mm 3 .
Data availability statement
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
References
1 Platt T , Ladd ME , Paech D . 7 Tesla and beyond: advanced methods and clinical applications in magnetic resonance imaging . Invest Radiol. 2021 ; 56 : 705 – 25 . 34510098 10.1097/RLI.0000000000000820 PMC8505159
2 Williams SN , Allwood‐Spiers S , Mcelhinney P , Paterson G , Herrler J , Liebig P , Nagel AM , et al. A nested eight‐channel transmit array with open‐face concept for human brain imaging at 7 Tesla . Front Phys. 2021 ; 9 : 701330 .
3 Knoll F , Hammernik K , Zhang C , Moeller S , Pock T , Sodickson DK , Akcakaya M . Deep‐learning methods for parallel magnetic resonance imaging reconstruction: a survey of the current approaches, trends, and issues . IEEE Signal Process Mag. 2020 ; 37 : 128 – 40 . 33758487 10.1109/MSP.2019.2950640 PMC7982984
4 Kwan JY , Jeong SY , Van Gelderen P , Deng H‐X , Quezado MM , Danielian LE , et al. Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 Tesla MRI and pathology . PLoS ONE. 2012 ; 7 : e35241 . 22529995 10.1371/journal.pone.0035241 PMC3328441
5 Cosottini M , Donatelli G , Costagli M , Caldarazzo Ienco E , Frosini D , Pesaresi I , et al. High‐resolution 7T MR imaging of the motor cortex in amyotrophic lateral sclerosis . AJNR Am J Neuroradiol. 2016 ; 37 : 455 – 61 . 26680464 10.3174/ajnr.A4562 PMC7960124
6 Düzel E , Costagli M , Donatelli G , Speck O , Cosottini M . studying Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis with 7 T magnetic resonance . Eur Radiol Exp. 2021 ; 5 : 36 . 34435242 10.1186/s41747-021-00221-5 PMC8387546
7 Zejlon C , Nakhostin D , Winklhofer S , Pangalu A , Kulcsar Z , Lewandowski S , et al. Structural magnetic resonance imaging findings and histopathological correlations in motor neuron diseases—a systematic review and meta‐analysis . Front Neurol. 2022 ; 13 : 947347 . 36110394 10.3389/fneur.2022.947347 PMC9468579
8 Chung HS , Melkus G , Bourque P , Chakraborty S . Motor band sign in motor neuron disease: a marker for upper motor neuron involvement . Can J Neurol Sci. 2023 ; 50 : 373 – 9 . 35477836 10.1017/cjn.2022.52
9 Costagli M , Donatelli G , Biagi L , Caldarazzo Ienco E , Siciliano G , Tosetti M , Cosottini M . Magnetic susceptibility in the deep layers of the primary motor cortex in amyotrophic lateral sclerosis . NeuroImage: Clin. 2016 ; 12 : 965 – 9 . 27995062 10.1016/j.nicl.2016.04.011 PMC5153607
10 Hecht MJ , Fellner F , Fellner C , Hilz MJ , Neundörfer B , Heuss D . Hyperintense and hypointense MRI signals of the precentral gyrus and corticospinal tract in ALS: a follow‐up examination including FLAIR images . J Neurol Sci. 2002 ; 199 : 59 – 65 . 12084444 10.1016/s0022-510x(02)00104-1
11 Van Lanen R , Colon AJ , Wiggins CJ , et al. Ultra‐high field magnetic resonance imaging in human epilepsy: a systematic review . NeuroImage: Clin. 2021 ; 30 : 102602 . 33652376 10.1016/j.nicl.2021.102602 PMC7921009
12 Colon AJ , Van Osch MJP , Buijs M , Grond JVD , Boon P , Van Buchem MA , Hofman PAM . Detection superiority of 7 T MRI protocol in patients with epilepsy and suspected focal cortical dysplasia . Acta Neurol Belg. 2016 ; 116 : 259 – 69 . 27389578 10.1007/s13760-016-0662-x PMC4989014
13 Veersema TJ , Ferrier CH , Van Eijsden P , Gosselaar PH , Aronica E , Visser F , et al. Seven Tesla MRI improves detection of focal cortical dysplasia in patients with refractory focal epilepsy . Epilepsia Open. 2017 ; 2 : 162 – 71 . 29588945 10.1002/epi4.12041 PMC5719847
14 Springer E , Dymerska B , Cardoso PL , Robinson SD , Weisstanner C , Wiest R , et al. Comparison of routine brain imaging at 3 T and 7 T . Invest Radiol. 2016 ; 51 : 469 – 82 . 26863580 10.1097/RLI.0000000000000256 PMC5704893
15 Wang I , Oh S , Blümcke I , Coras R , Krishnan B , Kim S , et al. Value of 7T MRI and post‐processing in patients with nonlesional 3T MRI undergoing epilepsy presurgical evaluation . Epilepsia. 2020 ; 61 : 2509 – 2520 . 32949471 10.1111/epi.16682 PMC7722133
16 Blumcke I , Spreafico R , Haaker G , Coras R , Kobow K , Bien CG , et al. Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery . N Engl J Med. 2017 ; 377 : 1648 – 56 . 29069555 10.1056/NEJMoa1703784
17 Urbach H , Kellner E , Kremers N , Blümcke I , Demerath T . MRI of focal cortical dysplasia . Neuroradiology. 2022 ; 64 : 443 – 52 . 34839379 10.1007/s00234-021-02865-x PMC8850246
18 Guye M , Bartolomei F , Ranjeva J‐P . Malformations of cortical development: the role of 7 Tesla magnetic resonance imaging in diagnosis . Rev Neurol (Paris). 2019 ; 175 : 157 – 62 . 30827579 10.1016/j.neurol.2019.01.393
19 Bartolini E , Cosottini M , Costagli M , et al. Ultra‐high‐field targeted imaging of focal cortical dysplasia: the intracortical black line sign in Type IIb . AJNR Am J Neuroradiol. 2019 ; 40 : 2137 – 2142 . 31727747 10.3174/ajnr.A6298 PMC6975359
20 De Ciantis A , Barba C , Tassi L , et al. 7T MRI in focal epilepsy with unrevealing conventional field strength imaging . Epilepsia. 2016 ; 57 : 445 – 54 . 26778405 10.1111/epi.13313
21 Okada T , Fujimoto K , Fushimi Y , Akasaka T , Thuy DHD , Shima A , et al. Neuroimaging at 7 Tesla: a pictorial narrative review . Quant Imag Med Surg. 2022 ; 12 : 3406 – 35 . 10.21037/qims-21-969 PMC9131333 35655840
22 Marques JP , Kober T , Krueger G , Van Der Zwaag W , Van De Moortele P‐F , Gruetter R . MP2RAGE, a self bias‐field corrected sequence for improved segmentation and T1‐mapping at high field . Neuroimage. 2010 ; 49 : 1271 – 81 . 19819338 10.1016/j.neuroimage.2009.10.002
23 Tang Y , Blümcke I , Su T‐Y , Choi JY , Krishnan B , Murakami H , et al. Black line sign in focal cortical dysplasia IIB: a 7T MRI and electroclinicopathologic study . Neurology. 2022 ; 99 : e616 – e626 . 35940890 10.1212/WNL.0000000000200702 PMC9442623
24 Anand K , Dhikav V . Hippocampus in health and disease: an overview . Ann Indian Acad Neurol. 2012 ; 15 : 239 . 23349586 10.4103/0972-2327.104323 PMC3548359
25 Zhang Y , Lv Y , You H , Dou W , Hou B , Shi L , et al. Study of the hippocampal internal architecture in temporal lobe epilepsy using 7 T and 3 T MRI . Seizure. 2019 ; 71 : 116 – 23 . 31325818 10.1016/j.seizure.2019.06.023
26 Blumcke I , Cross JH , Spreafico R . The international consensus classification for hippocampal sclerosis: an important step towards accurate prognosis . Lancet Neurol. 2013 ; 12 : 844 – 6 . 23948169 10.1016/S1474-4422(13)70175-3
27 Santyr BG , Goubran M , Lau JC , Kwan BYM , Salehi F , Lee DH , et al. Investigation of hippocampal substructures in focal temporal lobe epilepsy with and without hippocampal sclerosis at 7T . Magn Reson Imag. 2017 ; 45 : 1359 – 70 . 10.1002/jmri.25447 27564217
28 Breyer T , Wanke I , Maderwald S , Woermann FG , Kraff O , Theysohn JM , et al. Imaging of patients with hippocampal sclerosis at 7 Tesla . Acad Radiol. 2010 ; 17 : 421 – 6 . 20018529 10.1016/j.acra.2009.10.013
29 Stefanits H , Springer E , Pataraia E , Baumgartner C , Hainfellner JA , Prayer D , et al. Seven Tesla MRI of hippocampal sclerosis: an in vivo feasibility study with histological correlations . Invest Radiol. 2017 ; 52 : 666 – 71 . 28538339 10.1097/RLI.0000000000000388
30 De Ciantis A , Barkovich AJ , Cosottini M , et al. Ultra‐high‐field MR imaging in polymicrogyria and epilepsy . AJNR Am J Neuroradiol. 2015 ; 36 : 309 – 16 . 25258368 10.3174/ajnr.A4116 PMC5548091
31 Düzel E , Acosta‐Cabronero J , Berron D , Biessels GJ , Björkman‐Burtscher I , Bottlaender M , et al. European ultrahigh‐field imaging network for neurodegenerative diseases (EUFIND) . Alzheimers Dement (Amst). 2019 ; 11 : 538 – 49 . 31388558 10.1016/j.dadm.2019.04.010 PMC6675944
32 Donatelli G , Ceravolo R , Frosini D , Tosetti M , Bonuccelli U , Cosottini M . Present and future of ultra‐high field MRI in neurodegenerative disorders . Curr Neurol Neurosci Rep. 2018 ; 18 : 31 . 29679161 10.1007/s11910-018-0841-7
33 Thomas BP , Welch EB , Niederhauser BD , Whetsell WO , Anderson AW , Gore JC , et al. High‐resolution 7T MRI of the human hippocampus in vivo . Magn Reson Imag. 2008 ; 28 : 1266 – 72 . 10.1002/jmri.21576 PMC2669832 18972336
34 Wisse LEM , Biessels GJ , Heringa SM , Kuijf HJ , Koek D(H)L , Luijten PR , Geerlings MI . Hippocampal subfield volumes at 7T in early Alzheimer's disease and normal aging . Neurobiol Aging. 2014 ; 35 : 2039 – 45 . 24684788 10.1016/j.neurobiolaging.2014.02.021
35 Ali R , Goubran M , Choudhri O , Zeineh MM . Seven Tesla MRI and neuroimaging biomarkers for Alzheimer's disease . FOC. 2015 ; 39 : E4 . 10.3171/2015.9.FOCUS15326 26646928
36 Greenberg SM , Vernooij MW , Cordonnier C , Viswanathan A , Al‐Shahi Salman R , et al. Cerebral microbleeds: a guide to detection and interpretation . Lancet Neurol. 2009 ; 8 : 165 – 74 . 19161908 10.1016/S1474-4422(09)70013-4 PMC3414436
37 Brundel M , Heringa SM , De Bresser J , Koek HL , Zwanenburg JJM , Kappelle LJ , et al. High prevalence of cerebral microbleeds at 7 Tesla MRI in patients with early Alzheimer's disease . JAD. 2012 ; 31 : 259 – 63 . 22531417 10.3233/JAD-2012-120364
38 Greenberg SM , Bacskai BJ , Hernandez‐Guillamon M , Pruzin J , Sperling R , Van Veluw SJ . Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways . Nat Rev Neurol. 2020 ; 16 : 30 – 42 . 31827267 10.1038/s41582-019-0281-2 PMC7268202
39 Wu J‐J , Yao M , Ni J . Cerebral amyloid angiopathy‐related inflammation: current status and future implications . Chin Med J (Engl). 2021 ; 134 : 646 – 54 . 33625036 10.1097/CM9.0000000000001427 PMC7990003
40 Zhang Y , Chen H , Li R , Sterling K , Song W . Amyloid β‐based therapy for Alzheimer's disease: challenges, successes and future . Sig Transduct Target Ther. 2023 ; 8 : 248 . 10.1038/s41392-023-01484-7 PMC10310781 37386015
41 Anon . Leqembi recommended for treatment of early Alzheimer's disease . Amsterdam : European Medicines Agency (EMA) . https://www.ema.europa.eu/en/news/leqembi-recommended-treatment-early-alzheimers-disease
42 Sveikata L , Charidimou A , Viswanathan A . Vessels sing their ARIAs: the role of vascular amyloid in the age of Aducanumab . Stroke. 2022 ; 53 : 298 – 302 . 34905943 10.1161/STROKEAHA.121.036873
43 Sperling RA , Jack CR , Black SE , Frosch MP , Greenberg SM , Hyman BT , et al. Amyloid‐related imaging abnormalities in amyloid‐modifying therapeutic trials: recommendations from the Alzheimer's association research roundtable workgroup . Alzheimers Dement (Amst). 2011 ; 7 : 367 – 85 . 10.1016/j.jalz.2011.05.2351 PMC3693547 21784348
44 Thompson AJ , Banwell BL , Barkhof F , Carroll WM , Coetzee T , Comi G , et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria . Lancet Neurol. 2018 ; 17 : 162 – 73 . 29275977 10.1016/S1474-4422(17)30470-2
45 Filippi M , Bar‐Or A , Piehl F , Preziosa P , Solari A , Vukusic S , Rocca MA . Multiple sclerosis . Nat Rev Dis Primers. 2018 ; 4 : 43 . 30410033 10.1038/s41572-018-0041-4
46 Filippi M , Evangelou N , Kangarlu A , Inglese M , Mainero C , Horsfield MA , Rocca MA . Ultra‐high‐field MR imaging in multiple sclerosis . J Neurol Neurosur Psychiatry. 2014 ; 85 : 60 – 6 . 10.1136/jnnp-2013-305246 23813636
47 Montalban X . Revised McDonald criteria 2023 [Conference presentation]. ECTRIMS 2024 Convention, Copenhagen, Denmark. 2024 .
48 Filippi M , Brück W , Chard D , Fazekas F , Geurts JJG , Enzinger C , et al. Association between pathological and MRI findings in multiple sclerosis . Lancet Neurol. 2019 ; 18 : 198 – 210 . 30663609 10.1016/S1474-4422(18)30451-4
49 Spini M , Choi S , Harrison DM . 7T MPFLAIR versus MP2RAGE for quantifying lesion volume in multiple sclerosis . J Neuroimaging. 2020 ; 30 : 531 – 6 . 32569408 10.1111/jon.12718 PMC8080854
50 Mistry N , Tallantyre EC , Dixon JE , Galazis N , Jaspan T , Morgan PS , et al. Focal multiple sclerosis lesions abound in ‘normal appearing white matter’ . Mult Scler. 2011 ; 17 : 1313 – 23 . 21788249 10.1177/1352458511415305
51 Granberg T , Fan Q , Treaba CA , Ouellette R , Herranz E , Mangeat G , et al. In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis . Brain. 2017 ; 140 : 2912 – 26 . 29053798 10.1093/brain/awx247 PMC5841207
52 Treaba CA , Granberg TE , Sormani MP , Herranz E , Ouellette RA , Louapre C , et al. Longitudinal characterization of cortical lesion development and evolution in multiple sclerosis with 7.0 T MRI . Radiology. 2019 ; 291 : 740 – 9 . 30964421 10.1148/radiol.2019181719 PMC6543899
53 Calabrese M , Poretto V , Favaretto A , Alessio S , Bernardi V , Romualdi C , et al. Cortical lesion load associates with progression of disability in multiple sclerosis . Brain. 2012 ; 135 : 2952 – 61 . 23065788 10.1093/brain/aws246
54 Calabrese M , Agosta F , Rinaldi F , Mattisi I , Grossi P , Favaretto A , et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing‐remitting multiple sclerosis . Arch Neurol. 2009 ; 66 : 1144 – 50 . 19752305 10.1001/archneurol.2009.174
55 Pitt D , Boster A , Pei W , Wohleb E , Jasne A , Zachariah CR , et al. Imaging cortical lesions in multiple sclerosis with ultra–high‐field magnetic resonance imaging . Arch Neurol. 2010 ; 67 : 812 – 8 . 20625086 10.1001/archneurol.2010.148
56 Louapre C , Treaba CA , Barletta V , Mainero C . Ultra‐high field 7 T imaging in multiple sclerosis . Curr Opin Neurol. 2020 ; 33 : 422 – 9 . 32657883 10.1097/WCO.0000000000000839
57 Mainero C , Louapre C , Govindarajan ST , Giannì C , Nielsen AS , Cohen‐Adad J , et al. A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging . Brain. 2015 ; 138 : 932 – 45 . 25681411 10.1093/brain/awv011 PMC4677339
58 Huang W , Sweeney EM , Kaunzner UW , Wang Y , Gauthier SA , Nguyen TD . Quantitative susceptibility mapping versus phase imaging to identify multiple sclerosis iron rim lesions with demyelination . J Neuroimaging. 2022 ; 32 : 667 – 75 . 35262241 10.1111/jon.12987 PMC9308704
59 Lassmann H . Multiple sclerosis pathology . Cold Spring Harb Perspect Med. 2018 ; 8 : a028936 . 29358320 10.1101/cshperspect.a028936 PMC5830904
60 Dal‐Bianco A , Grabner G , Kronnerwetter C , Weber M , Kornek B , Kasprian G , et al. Long‐term evolution of multiple sclerosis iron rim lesions in 7 T MRI . Brain. 2021 ; 144 : 833 – 47 . 33484118 10.1093/brain/awaa436
61 Treaba CA , Conti A , Klawiter EC , Barletta VT , Herranz E , Mehndiratta A , et al. Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression . Brain Commun. 2021 ; 3 : fcab134 . 34704024 10.1093/braincomms/fcab134 PMC8361394
62 Vanden Bulcke C , Stölting A , Maric D , Macq B , Absinta M , Maggi P . Comparative overview of multi‐shell diffusion MRI models to characterize the microstructure of multiple sclerosis lesions and periplaques . NeuroImage: Clin. 2024 ; 42 : 103593 . 38520830 10.1016/j.nicl.2024.103593 PMC10978527
63 Choi S , Lake S , Harrison DM . Evaluation of the blood‐brain barrier, demyelination, and neurodegeneration in paramagnetic rim lesions in multiple sclerosis on 7 Tesla MRI . Magn Reson Imag. 2024 ; 59 : 941 – 951 . 10.1002/jmri.28847 PMC10754232 37276054
64 Tallantyre EC , Morgan PS , Dixon JE , Al‐Radaideh A , Brookes MJ , Evangelou N , Morris PG . A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions : Invest Radiol. 2009 ; 44 : 491 – 4 . 10.1097/RLI.0b013e3181b4c144 19652606
65 Okromelidze L , Patel V , Singh RB , Lopez Chiriboga AS , Tao S , Zhou X , et al. Central vein sign in multiple sclerosis: a comparison study of the diagnostic performance of 3T versus 7T MRI . AJNR Am J Neuroradiol. 2024 ; 45 : 76 – 81 . 10.3174/ajnr.A8083 PMC10756573 38164557
66 Liu Z , Pardini M , Yaldizli Ö , Sethi V , Muhlert N , Wheeler‐Kingshott CAM , et al. Magnetization transfer ratio measures in normal‐appearing white matter show periventricular gradient abnormalities in multiple sclerosis . Brain. 2015 ; 138 : 1239 – 46 . 25823475 10.1093/brain/awv065 PMC5963416
67 Harrison DM , Wang KY , Fiol J , Naunton K , Royal W , Hua J , et al. Leptomeningeal enhancement at 7T in multiple sclerosis: frequency, morphology, and relationship to cortical volume . J Neuroimaging. 2017 ; 27 : 461 – 8 . 28464368 10.1111/jon.12444 PMC5581238
68 Filippi M , Preziosa P , Arnold DL , Barkhof F , Harrison DM , Maggi P , et al. Present and future of the diagnostic work‐up of multiple sclerosis: the imaging perspective . J Neurol. 2023 ; 270 : 1286 – 99 . 36427168 10.1007/s00415-022-11488-y PMC9971159
69 Ineichen BV , Tsagkas C , Absinta M , Reich DS . Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: a systematic review and meta‐analysis . NeuroImage: Clin. 2022 ; 33 : 102939 . 35026625 10.1016/j.nicl.2022.102939 PMC8760523
70 Hayes MT . Parkinson's disease and parkinsonism . Am J Med. 2019 ; 132 : 802 – 807 . 30890425 10.1016/j.amjmed.2019.03.001
71 Bae YJ , Kim J‐M , Sohn C‐H , Choi J‐H , Choi BS , Song YS , et al. Imaging the substantia nigra in Parkinson disease and other parkinsonian syndromes . Radiology 2021 ; 300 : 260 – 278 . 34100679 10.1148/radiol.2021203341
72 Dickson DW . Parkinson's disease and parkinsonism: neuropathology . Cold Spring Harb Perspect Med. 2012 ; 2 : a009258 – a009258 . 22908195 10.1101/cshperspect.a009258 PMC3405828
73 Johnson ML , Lewis MM , Wang EW , Jellen LC , Du G , De Jesus S , et al. Neuropathological findings and in vivo imaging correlates of the red nucleus compared to those of the substantia nigra pars compacta in parkinsonisms . Parkinsonism Relat Disord. 2024 ; 125 : 107043 . 38896976 10.1016/j.parkreldis.2024.107043 PMC11283947
74 Ladd ME , Bachert P , Meyerspeer M , Moser E , Nagel AM , Norris DG , et al. Pros and cons of ultra‐high‐field MRI/MRS for human application . Prog Nucl Magn Reson Spectrosc. 2018 ; 109 : 1 – 50 . 30527132 10.1016/j.pnmrs.2018.06.001
75 Abosch A , Yacoub E , Ugurbil K , Harel N . An assessment of current brain targets for deep brain stimulation surgery with susceptibility‐weighted imaging at 7 Tesla . Neurosur. 2010 ; 67 : 1745 – 56 . 10.1227/NEU.0b013e3181f74105 PMC3124849 21107206
76 Lakhani DA , Zhou X , Tao S , Patel V , Wen S , Okromelidze L , et al. Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson's disease . npj Parkinsons Dis. 2024 ; 10 : 13 . 38191546 10.1038/s41531-024-00631-3 PMC10774294
77 Shams S , Fällmar D , Schwarz S , Wahlund L‐O , Van Westen D , Hansson O , et al. MRI of the swallow tail sign: a useful marker in the diagnosis of lewy body dementia? AJNR Am J Neuroradiol. 2017 ; 38 : 1737 – 41 . 28705819 10.3174/ajnr.A5274 PMC7963704
78 Blazejewska AI , Schwarz ST , Pitiot A , Stephenson MC , Lowe J , Bajaj N , et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI . Neurology. 2013 ; 81 : 534 – 40 . 23843466 10.1212/WNL.0b013e31829e6fd2 PMC3775686
79 Schmidt MA , Engelhorn T , Marxreiter F , Winkler J , Lang S , Kloska S , et al. Ultra high‐field SWI of the substantia nigra at 7T: reliability and consistency of the swallow‐tail sign . BMC Neurol. 2017 ; 17 : 194 . 29073886 10.1186/s12883-017-0975-2 PMC5658950
80 Cosottini M , Frosini D , Pesaresi I , Costagli M , Biagi L , Ceravolo R , et al. MR imaging of the substantia nigra at 7 T enables diagnosis of parkinson disease . Radiology. 2014 ; 271 : 831 – 8 . 24601752 10.1148/radiol.14131448
81 Wang Y , Liu T . Quantitative susceptibility mapping (QSM): decoding MRI data for a tissue magnetic biomarker . Magn Reson Med. 2015 ; 73 : 82 – 101 . 25044035 10.1002/mrm.25358 PMC4297605
82 Langkammer C , Pirpamer L , Seiler S , Deistung A , Schweser F , Franthal S , et al. Quantitative susceptibility mapping in Parkinson's disease . PLoS ONE. 2016 ; 11 : e0162460 . 27598250 10.1371/journal.pone.0162460 PMC5012676
83 Lotfipour AK , Wharton S , Schwarz ST , Gontu V , Schäfer A , Peters AM , et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease . Magn Reson Imag. 2012 ; 35 : 48 – 55 . 10.1002/jmri.22752 21987471
84 Eskreis‐Winkler S , Zhang Y , Zhang J , Liu Z , Dimov A , Gupta A , et al. The clinical utility of QSM: disease diagnosis, medical management, and surgical planning . NMR Biomed. 2017 ; 30 : e3668 . 10.1002/nbm.3668 27906525
85 Haacke EM , Makki M , Ge Y , Maheshwari M , Sehgal V , Hu J , et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging . J Magn Reson Imag. 2009 ; 29 : 537 – 44 . 10.1002/jmri.21676 PMC2650739 19243035
86 Shmueli K , de Zwart JA , van Gelderen P , Li T‐Q , Dodd SJ , Duyn JH . Magnetic susceptibility mapping of brain tissue in vivo using MRI phase data . Magn Reson Med. 2009 ; 62 : 1510 – 22 . 19859937 10.1002/mrm.22135 PMC4275127
87 Sjöström H , Granberg T , Westman E , Svenningsson P . Quantitative susceptibility mapping differentiates between parkinsonian disorders . Parkinsonism Relat Disord. 2017 ; 44 : 51 – 57 . 28886909 10.1016/j.parkreldis.2017.08.029
88 Cheng K , Duan Q , Hu J , Li C , Ma X , Bian X , et al. Evaluation of postcontrast images of intracranial tumors at 7 T and 3 T MRI: an intra‐individual comparison study . CNS Neurosci Ther. 2023 ; 29 : 559 – 565 36468424 10.1111/cns.14036 PMC9873521
89 Shaffer A , Kwok SS , Naik A , Anderson AT , Lam F , Wszalek T , et al. Ultra‐high‐field MRI in the diagnosis and management of gliomas: a systematic review . Front Neurol. 2022 ; 13 : 857825 . 35449515 10.3389/fneur.2022.857825 PMC9016277
90 Compter I , Peerlings J , Eekers DBP , Postma AA , Ivanov D , Wiggins CJ , et al. Technical feasibility of integrating 7 T anatomical MRI in image‐guided radiotherapy of glioblastoma: a preparatory study . Magn Reson Mater Phy. 2016 ; 29 : 591 – 603 . 10.1007/s10334-016-0534-7 27026245
91 Grabner G , Nöbauer I , Elandt K , Kronnerwetter C , Woehrer A , Marosi C , et al. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility‐weighted magnetic resonance imaging at 7 T . Magn Reson Imag. 2012 ; 30 : 139 – 47 . 10.1016/j.mri.2011.08.004 21982163
92 Di Ieva A , Matula C , Grizzi F , Grabner G , Trattnig S , Tschabitscher M . Fractal analysis of the susceptibility weighted imaging patterns in malignant brain tumors during antiangiogenic treatment: technical report on four cases serially imaged by 7 T magnetic resonance during a period of four weeks . World Neurosurg. 2012 ; 77 : 785.e11 – 785.e21 . 10.1016/j.wneu.2011.09.006 22120276
93 Lupo JM , Chuang CF , Chang SM , Barani IJ , Jimenez B , Hess CP , et al. 7 Tesla susceptibility‐weighted imaging to assess the effects of radiotherapy on normal‐appearing brain in patients with glioma . Int J Radiat Oncol Biol Phys. 2012 ; 82 : e493 – 500 . 22000750 10.1016/j.ijrobp.2011.05.046 PMC3268881
94 Grabner G , Kiesel B , Wöhrer A , Millesi M , Wurzer A , Göd S , et al. Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status . Eur Radiol. 2017 ; 27 : 1556 – 67 . 27300198 10.1007/s00330-016-4451-y PMC5334387
95 Wen Q , Kelley DAC , Banerjee S , Lupo JM , Chang SM , Xu D , et al. Clinically feasible NODDI characterization of glioma using multiband EPI at 7 T . NeuroImage: Clin. 2015 ; 9 : 291 – 9 . 26509116 10.1016/j.nicl.2015.08.017 PMC4579286
96 Kiruluta AJM , González RG . Magnetic resonance angiography . In: Handbook of clinical neurology . Amsterdam : Elsevier ; 2016 . p. 137 – 49 . 10.1016/B978-0-444-53485-9.00007-6 27432663
97 Willinsky RA , Taylor SM , terBrugge K , Farb RI , Tomlinson G , Montanera W . Neurologic complications of cerebral angiography: prospective analysis of 2,899 procedures and review of the literature . Radiology. 2003 ; 227 : 522 – 8 . 12637677 10.1148/radiol.2272012071
98 Von Morze C , Xu D , Purcell DD , et al. Intracranial time‐of‐flight MR angiography at 7T with comparison to 3T . Magn Reson Imag. 2007 ; 26 : 900 – 4 . 10.1002/jmri.21097 17896360
99 Fuster V , Moreno PR , Fayad ZA , Corti R , Badimon JJ . Atherothrombosis and high‐risk plaque . J Am Coll Cardiol. 2005 ; 46 : 937 – 54 . 16168274 10.1016/j.jacc.2005.03.074
100 Mandell DM , Mossa‐Basha M , Qiao Y , Hess CP , Hui F , Matouk C , et al. Intracranial vessel wall MRI: principles and expert consensus recommendations of the american society of neuroradiology . AJNR Am J Neuroradiol. 2017 ; 38 : 218 – 29 . 27469212 10.3174/ajnr.A4893 PMC7963837
101 Van Der Kolk AG , Hendrikse J , Brundel M , Biessels GJ , Smit EJ , et al. Multi‐sequence whole‐brain intracranial vessel wall imaging at 7.0 Tesla . Eur Radiol. 2013 ; 23 : 2996 – 3004 . 23736375 10.1007/s00330-013-2905-z
102 Harteveld AA , Van Der Kolk AG , Van Der Worp HB , Dieleman N , Siero JCW , Kuijf HJ , et al. High‐resolution intracranial vessel wall MRI in an elderly asymptomatic population: comparison of 3T and 7T . Eur Radiol. 2017 ; 27 : 1585 – 95 . 27387876 10.1007/s00330-016-4483-3 PMC5334422
103 Brown RD , Broderick JP . Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screening . Lancet Neurol. 2014 ; 13 : 393 – 404 . 24646873 10.1016/S1474-4422(14)70015-8
104 Samaniego EA , Roa JA , Hasan D . Vessel wall imaging in intracranial aneurysms . J Neurointerv Surg. 2019 ; 11 : 1105 – 12 . 31337731 10.1136/neurintsurg-2019-014938
105 Salvarani C , Brown RD , Hunder GG . Adult primary central nervous system vasculitis . Lancet. 2012 ; 380 : 767 – 77 . 22575778 10.1016/S0140-6736(12)60069-5
106 Swartz RH , Bhuta SS , Farb RI , Agid R , Willinsky RA , Terbrugge KG , et al. Intracranial arterial wall imaging using high‐resolution 3 Tesla contrast‐enhanced MRI . Neurology. 2009 ; 72 : 627 – 4 . 19221296 10.1212/01.wnl.0000342470.69739.b3
107 Lawton MT , Rutledge WC , Kim H , Stapf C , Whitehead KJ , Li DY , et al. Brain arteriovenous malformations . Nat Rev Dis Primers. 2015 ; 1 : 15008 . 27188382 10.1038/nrdp.2015.8
108 Wrede KH , Dammann P , Johst S , Mönninghoff C , Schlamann M , Maderwald S , et al. Non‐enhanced MR imaging of cerebral arteriovenous malformations at 7 Tesla . Eur Radiol. 2016 ; 26 : 829 – 39 . 26080795 10.1007/s00330-015-3875-0
109 Schnell S , Wu C , Ansari SA . Four‐dimensional MRI flow examinations in cerebral and extracerebral vessels – ready for clinical routine? Curr Opin Neurol. 2016 ; 29 : 419 – 28 . 27262148 10.1097/WCO.0000000000000341 PMC4939804
110 Bertalanffy H , Benes L , Miyazawa T , Alberti O , Siegel AM , Sure U . Cerebral cavernomas in the adult. Review of the literature and analysis of 72 surgically treated patients . Neurosurg Rev. 2002 ; 25 : 1 – 53 11954761 10.1007/s101430100179
111 Dammann P , Barth M , Zhu Y , Maderwald S , Schlamann M , Ladd ME , et al. Susceptibility weighted magnetic resonance imaging of cerebral cavernous malformations: prospects, drawbacks, and first experience at ultra–high field strength (7 Tesla) magnetic resonance imaging . FOC. 2010 ; 29 : E5 . 10.3171/2010.6.FOCUS10130 20809763
112 Specht K . Current challenges in translational and clinical fMRI and future directions . Front Psychiatry. 2020 ; 10 : 924 . 31969840 10.3389/fpsyt.2019.00924 PMC6960120
113 Eisenstein M . Pushing the limits of MRI brain imaging . Nat Methods. 2024 ; 21 : 1975 – 9 . 39511349 10.1038/s41592-024-02489-y
114 Foerster BR , Welsh RC , Feldman EL . 25 years of neuroimaging in amyotrophic lateral sclerosis . Nat Rev Neurol. 2013 ; 9 : 513 – 24 . 23917850 10.1038/nrneurol.2013.153 PMC4182931
115 Barisano G , Sepehrband F , Ma S , Jann K , Cabeen R , Wang DJ , et al. Clinical 7 T MRI: are we there yet? a review about magnetic resonance imaging at ultra‐high field . Br J Radiol. 2019 ; 92 : 20180492 . 30359093 10.1259/bjr.20180492 PMC6404849
116 Kalra S . Magnetic resonance spectroscopy in ALS . Front Neurol. 2019 ; 10 : 482 . 31133975 10.3389/fneur.2019.00482 PMC6524558
117 Cheong I , Marjańska M , Deelchand DK , Eberly LE , Walk D , Öz G . Ultra‐high field proton MR spectroscopy in early‐stage amyotrophic lateral sclerosis . Neurochem Res. 2017 ; 42 : 1833 – 44 . 28367604 10.1007/s11064-017-2248-2 PMC5488866
118 Zaiss M , Windschuh J , Paech D , Meissner J‐E , Burth S , Schmitt B , et al. Relaxation‐compensated CEST‐MRI of the human brain at 7 T: unbiased insight into NOE and amide signal changes in human glioblastoma . Neuroimage. 2015 ; 112 : 180 – 8 . 25727379 10.1016/j.neuroimage.2015.02.040
119 Neal A , Moffat BA , Stein JM , Nanga RPR , Desmond P , Shinohara RT , et al. Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging . NeuroImage: Clin. 2019 ; 22 : 101694 . 30822716 10.1016/j.nicl.2019.101694 PMC6396013
120 Heo H‐Y , Jones CK , Hua J , Yadav N , Agarwal S , Zhou J , et al. Whole‐brain amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging in glioma patients using low‐power steady‐state pulsed chemical exchange saturation transfer (CEST) imaging at 7T . Magn Reson Imag. 2016 ; 44 : 41 – 50 . 10.1002/jmri.25108 PMC4902781 26663561
121 Paech D , Windschuh J , Oberhollenzer J , Dreher C , Sahm F , Meissner J‐E , et al. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation‐compensated multipool CEST MRI at 7.0 T . Neuro Oncol. 2018 ; 20 : 1661 – 71 . 29733378 10.1093/neuonc/noy073 PMC6231210
122 Huang J , Chen Z , Park S‐W , Lai JHC , Chan KWY . Molecular imaging of brain tumors and drug delivery using CEST MRI: promises and challenges . Pharmaceutics. 2022 ; 14 : 451 . 35214183 10.3390/pharmaceutics14020451 PMC8880023
123 Xu X , Yadav NN , Knutsson L , Hua J , Kalyani R , Hall E , et al. Dynamic glucose‐enhanced (DGE) MRI: translation to human scanning and first results in glioma patients . Tomography. 2015 ; 1 : 105 – 14 . 26779568 10.18383/j.tom.2015.00175 PMC4710854
124 Paech D , Schuenke P , Koehler C , Windschuh J , Mundiyanapurath S , Bickelhaupt S , et al. T1ρ‐weighted dynamic glucose‐enhanced MR imaging in the human brain . Radiology. 2017 ; 285 : 914 – 22 . 28628422 10.1148/radiol.2017162351
125 Schuenke P , Koehler C , Korzowski A , Windschuh J , Bachert P , Ladd ME , et al. Adiabatically prepared spin‐lock approach for T1ρ‐based dynamic glucose enhanced MRI at ultrahigh fields . Magn Reson Med. 2017 ; 78 : 215 – 25 . 27521026 10.1002/mrm.26370
126 Choi C‐H , Hong S‐M , Felder J , Shah NJ . The state‐of‐the‐art and emerging design approaches of double‐tuned RF coils for X‐nuclei, brain MR imaging and spectroscopy: a review . Magn Reson Imag. 2020 ; 72 : 103 – 16 . 10.1016/j.mri.2020.07.003 32653426
127 Wang G , Yang H , Li J , Wen J , Zhong K , Tian C . Overview and progress of X‐nuclei magnetic resonance imaging in biomedical studies . Magn Reson Lett. 2023 ; 3 : 327 – 43 . 10.1016/j.mrl.2023.05.002 PMC12406619 40919505
128 Hu R , Kleimaier D , Malzacher M , Hoesl MAU , Paschke NK , Schad LR . X‐nuclei imaging: current state, technical challenges, and future directions . Magn Reson Imag. 2020 ; 51 : 355 – 76 . 10.1002/jmri.26780 31102340
129 Schmidt T , Lee Y , Nagy Z . Custom integration of a magnetic‐field monitoring system into a 32‐channel MRI head coil . Magn Reson Med. 2025 ; 93 : 889 – 98 . 39344211 10.1002/mrm.30314 PMC11604842
130 Feinberg DA , Beckett AJS , Vu AT , Stockmann J , Huber L , Ma S , et al. Next‐generation MRI scanner designed for ultra‐high‐resolution human brain imaging at 7 Tesla . Nat Methods. 2023 ; 20 : 2048 – 57 . 38012321 10.1038/s41592-023-02068-7 PMC10703687
131 Bates S , Dumoulin SO , Folkers PJM , Formisano E , Goebel R , Haghnejad A , et al. A vision of 14 T MR for fundamental and clinical science . Magn Reson Mater Phy. 2023 ; 36 : 211 – 25 . 10.1007/s10334-023-01081-3 PMC10088620 37036574